Use of B-Type Natriuretic Peptide in the Risk Stratification of Acute Exacerbations of COPD
Authors:
- Tobias BreidthardtTBTobias Breidthardt
- Mirjam Christ-CrainMCMirjam Christ-Crain
- Roland BingisserRBRoland Bingisser
- David MiedingerDMDavid Miedinger
- Jörg LeuppiJLJörg Leuppi
- Beat MuellerBMBeat Mueller
- Michael TammMTMichael Tamm
- Christian MuellerCMChristian Mueller
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Long‐term prognostic value of B‐type natriuretic peptide in cardiac and non‐cardiac causes of acute dyspnoeaEuropean Journal of Clinical Investigation, 2007
- Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint CommitteeThorax, 2007
- Antibiotic Treatment of Exacerbations of COPDChest, 2007
- Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary diseaseAmerican Heart Journal, 2006
- Serum vasopressin concentrations in critically ill patients*Critical Care Medicine, 2006
- Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of VasopressinClinical Chemistry, 2006
- B‐type natriuretic peptide for risk stratification in community‐acquired pneumoniaJournal of Internal Medicine, 2005
- Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinaseJournal of Molecular and Cellular Cardiology, 2004
- Arginine Vasopressin in Advanced Vasodilatory ShockCirculation, 2003
- Hormones and Hemodynamics in Heart FailureNew England Journal of Medicine, 1999